AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Tempus AI, Inc.
Video analysis: TEM
All videosNo video analysis for this stock yet. Request one from our team.
News: TEM
REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine
Tempus CEO Eric Lefkofsky discusses the company's artificial intelligence-driven precision medicine partnership with Merck on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #tempus #ericlefkofsky #lefkofsky #merck #ai #artificialintelligence #healthcare #precisionmedicine #medicine #medicalresearch #technology #clinicaldata #patientcare #healthtech
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical inform
Nvidia, Snowflake, Chubb And A Health Care Stock On CNBC's ‘Final Trades'
On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Snowflake Inc. (NYSE:SNOW).
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically optimized for AI-driven research. Once this dataset is complete, Tempus plans to expand the effort with the goal o.
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H's ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmati.
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global H
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of t.
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
Similar companies
-
Doximity, Inc.
DOCS
·
New York Stock Exchange
Compare
-
Smith & Nephew plc
SNN
·
New York Stock Exchange
Compare
-
Fresenius Medical Care AG & Co. KGaA
FMS
·
New York Stock Exchange
Compare
-
The Cooper Companies, Inc.
COO
·
NASDAQ
Compare
-
Medpace Holdings, Inc.
MEDP
·
NASDAQ
Compare
-
Neurocrine Biosciences, Inc.
NBIX
·
NASDAQ
Compare